Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque Psoriasis

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!